Evaluation of Oral Isotretinoin Effects on Hearing System in Patients with Acne Vulgaris: Reversible or Not?

pay.thelady61 shared this article with you from Inoreader Original Article: Evaluation of Oral Isotretinoin Effects on Hearing System in Patients with Acne Vulgaris: Reversible or Not? Via Dermatologic Therapy Abstract Background Systemic Isotretinoin is commonly used for severe acne treatment. It has many side effects, one of these is about hearing system which have rarely been reported, also previous studies reported contradictory results about systemic isotretinoin and its association with hearing system. In this study, we aimed to investigate whether systemic isotretinoin affected on the hearing system or not. Materials and Methods The study included 32 acne vulgaris patients (64 ears) who treated with oral isotretinoin 0.5 mg/kg body weight for at least four months and audiometric tests including pure‐tone, speech, bilateral acoustic reflexes and tympanometric measurements were performed at baseline, in the first week, in the first month, and third month of treatment and sixth month after treatment. Audiometric tests were performed for right and left ears separately. Results A significant difference was found in the pure‐tone thresholds (before treatment, first week, first month, third month of treatment and sixth month after treatment) for the both ears at 8000Hz (p<0.001) and a significant decrease in the sixth month post‐treatment pure‐tone thresholds compared to pre‐treatment thresholds at 8000 Hz. Additionally, a statistically significant increase was observed in serum LDL and triglyceride levels in the third month of treatment and a significant decrease at the sixth month after treatment (p<0.001). Conclusion Systemic isotretinoin caused bilateral hearing threshold changes in acne patients during the therapy but the changes improved after discontinuation. Therefore, our findings may provide safety using for dermatologists about hearing effects of isotretinoin which is quite effective on severe acne. This article is protected by copyright. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Losartan for treatment of epidermolysis bullosa – a new perspective

pay.thelady61 shared this article with you from Inoreader Losartan for treatment of epidermolysis bullosa – a new perspective Via Dermatologic Therapy View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

investigation of thyroid blood tests and thyroid ultrasound findings of patients with rosacea

pay.thelady61 shared this article with you from Inoreader investigation of thyroid blood tests and thyroid ultrasound findings of patients with rosacea Via Dermatologic Therapy Abstract Background We aimed to investigate the relationship between rosacea and thyroid diseases by analyzing thyroid blood tests and ultrasound findings of our patients recently diagnosed with rosacea. Methods This study was designed as a prospective, single‐center study. Dermatological examination findings, lesion locations were recorded, and rosacea clinical scores were calculated for all study group patients. The control group consisted of completely healthy women presented to our hospital during the study period for check‐up purposes. Serum free thyroxine, free triiodothyronine, thyroid‐stimulating hormone, anti‐thyroglobulin antibody, anti‐thyroid peroxidase antibody levels were measured, and thyroid ultrasound examinations were performed for all study participants. Results The entire study cohort consisted of 123 patients (63 cases and 60 controls). There was no significant difference between the groups in terms of mean patient age (p<0,05). Cheek was the most common lesion location (96.8%). There was no difference between the groups in terms of thyroid‐related laboratory parameters. However, anti‐TPO levels differed significantly with increasing disease severity (i.e., RCSs). There were significant relationships between cheek lesions and fT4 (p=0.021), while nose and chin lesions were associated with fT3 (p=0.01, p=0.001). Thyroid ultrasound findings revealed that rosacea patients tended to have larger thyroid nodules and more heterogeneous thyroid parenchymas than controls. Conclusions Our findings indicate that thyroid blood tests, including thyroid autoantibodies, should be tested and thyroid ultrasounds should be performed in patients diagnosed with rosacea. However, these findings need to be validated by prospective studies conducted in larger patient series with more extended follow‐up periods. This article is protected by copyright. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Rituximab in Practice: Clinical Evaluation of Patients with Pemphigus after Rituximab Administration

pay.thelady61 shared this article with you from Inoreader Rituximab in Practice: Clinical Evaluation of Patients with Pemphigus after Rituximab Administration Via Dermatologic Therapy Abstract Pemphigus Vulgaris (PV) is a rare autoimmune blistering disease, which mainly causes mucosal and/or cutaneous lesions. In June 2018, FDA approved Rituximab (RTX)‐ a B‐cell depleting agent‐ for the management of patients with moderate‐to‐severe pemphigus. Although the majority of patients respond well to this drug, some do not reach complete remission with a single cycle of RTX. In this review, following an overview of RTX and its clinical outcomes, we have focused on the possible outcomes after RTX therapy in patients with PV. The response is defined into four main categories; complete responders, partial responders, non‐responders, and paradoxical reactions, based on three possibilities of reaching the consolidation phase after three months, reaching remission until six months, and the ability of corticosteroid tapering in six months after RTX administration. Concerning the safety of RTX, three categories of infusion reactions, short and long‐term side effects are d iscussed. Additionally, we have suggested approaches for the evaluation of clinical and serological responses at different critical time‐points, including one, two, three, and six months after RTX administration. Finally, available markers to predict the response to RTX and research gaps in the field of RTX therapy have been summarized. This article is protected by copyright. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

The Most Common Allergens

pay.thelady61 shared this article with you from Inoreader The Most Common Allergens According to Skin Prick Test: The Role of Wheal Diameter in Clinical Relevancy Via Dermatologic Therapy Abstract Background The skin prick test (SPT) could be applied as a useful in vivo method for the detection of sensitization in epidemiological and diagnostic studies if the wheal size is ideally evaluated. We focused on SPT wheal size to identify sensitization pattern to common inhalant and food allergens. Methods In this cross‐sectional study, SPT results were obtained from a total of 972 allergic patients. Common allergen extracts for SPT were selected according to the type of allergic diseases, and the geographical pattern. SPT with food allergens was performed for patients with atopic dermatitis (AD) and chronic urticaria (CU). Results A total of 461 male (47.4%) and 511 female (52.6%) participated in this study (median age: 31 years). The majority of individuals were affected with allergic rhinitis (AR) (n=624) and asthma (n=224); while 129 and 67 patients suffered from AD and CU, respectively. The most common aeroallergens were Russian thistle (52.1%) and Lamb's Quarter (50.7%) with the largest wheal diameter. The wheal size of lamb's quarter was significantly different between patients with asthma and AR (P<0.001). In addition, a significant difference was detected in wheal diameter in response to the Russian thistle between patients with AR and AD (P=0.001). Shrimp (23.6%) and Peanut (22.5%) caused the most common food sensitization in patients with AD and CU. Conclusion Having in mind the most common weed pollens including the Russian thistle and Lamb's Quarter, preventive strategies such as removing unwanted weeds or preventing them from growing, avoidance, and specific immunotherapy may be crucial for better disease control. This article is protected by copyright. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

The risk for severe COVID 19 in patients with autoimmune and/or inflammatory diseases: First wave lessons

pay.thelady61 shared this article with you from Inoreader The risk for severe COVID 19 in patients with autoimmune and/or inflammatory diseases: First wave lessons Via Dermatologic Therapy Abstract Data regarding the risk for severe COVID19 in patients with autoimmune or inflammatory diseases are scarce. To estimate the risk of those patients to develop a more severe COVID19 infection All active patients and those with dermatologic and/or rheumatologic autoimmune/inflammatory diseases were identified in a single tertiary center. The charts of those tested positive for COVID19 between March 1stand May 31st, 2020 reviewed including demographics, co‐morbidities and medications. COVID19 outcome of those with dermatologic and/or rheumatologic autoimmune/inflammatory diseases were compared to COVID19 infected matched controls without an autoimmune/inflammatory background. Overall, 974 of 381 268 active patients were tested positive for COVID19, including 35 out of 13 225 with dermatologic and/or rheumatologic autoimmune/inflammatory diseases. No statistically significant difference in severity of COVID19 infection or mortality rate was found. The rate of asymptoma tic, mild, moderate, severe/critical and fatal COVID19 infection was 11.4%, 37.1%, 22.8%, 11.4% and 17.1% respectively for the patients with autoimmune diseases and 17.8%, 45.8%, 10.9%, 6.8% and 18.4% respectively for the controls . Patients with autoimmune/inflammatory diseases seem not to develop a more severe COVID19 infection than controls. This article is protected by copyright. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Hypertrichosis and hair repigmentation in patients receiving interleukin‐17A inhibitors

pay.thelady61 shared this article with you from Inoreader Hypertrichosis and hair repigmentation in patients receiving interleukin‐17A inhibitors Via Dermatologic Therapy View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.